The National Command and Operation Center (NCOC) on Tuesday reported the dispatch of stage 3 clinical preliminaries in Pakistan for a potential antibody being created by China's CanSino Biologics for the novel Covid. 

Preliminaries for stage 1 and 2 for the antibody were held in China. Pakistan, under a public-private association between the National Institute of Health (NIH) and CanSino, is among the nations which will do stage 3, the NCOC proclamation said. 

The nation's medication controller a month ago gave the approval for the nation's first stage 3 clinical preliminary for CanSino's competitor.

Image source. https://i.dawn.com/primary/2020/09/5f69a739314b3.png